Results 131 to 140 of about 63,989 (248)

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach

Chemistry Central Journal, 2017
Background Rivaroxaban is a direct inhibitor of coagulation factor Xa and is used for venous thromboembolic disorders. The rivaroxaban interaction with BSA was studied to understand its PK and PD (pharmacokinetics and pharmacokinetics) properties.
Tanveer A. Wani, Haitham AlRabiah, Ahmed H. Bakheit, Mohd Abul Kalam, Seema Zargar   +4 more
doaj   +1 more source

Healthcare Resource Utilisation and Cost of Obesity and Related Complications in the United States: A Systematic Literature Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4121-4136, May 2026.
ABSTRACT Aim Obesity is an increasingly prevalent, chronic, heterogeneous disease, associated with a variety of obesity‐related complications (ORCs). This systematic literature review assessed US healthcare resource utilisation (HCRU) and costs (direct and indirect) for people living with obesity (PwO) or overweight and ORCs.
Jaime P. Almandoz, Jamy D. Ard, Chellse Gazda, Shenelle Edwards‐Hampton   +3 more
wiley   +1 more source

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source

Efficacy Comparison of Open Reduction and Robot‐Aided Infra‐Acetabular and Posterior Column Screws Fixation in Complex Acetabular Fractures Surgery: Union Plate Versus Reconstruction Plate

Orthopaedic Surgery, Volume 18, Issue 5, Page 999-1009, May 2026.
Robot‐aided technology allowed for precise and minimally invasive placement of periarticular long screws in open surgery for complex acetabular fractures, while using the Union Plate could decrease operation difficulty (fewer channel adjustments, less time for robotic manipulation and intraoperative plate contouring), operation time, and bleeding.
Jianan Chen, Yiran Feng, Runlin Zhu, Pengqing Zhang, Zhihua Zhao, Ziming Zhang, Xiaodong Guo, Lulu Tang, Kaifang Chen   +8 more
wiley   +1 more source

XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. [PDF]

, 2018
Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit-risk profile ...
Camm, AJ, Kim, Y-H, Kurniawan, M, Li Fern, H, Maskon, O, Muengtaweepongsa, S, Nguyen, TH, Shim, J, Sim, K, Thanachartwet, T, Tsai, C-T, Vilela, G, Wang, C-C, XANAP investigators   +13 more
core   +1 more source

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +1 more source

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

Pharmaceuticals, 2012
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk of ...
Michael Becka, Wolfgang Mück, Stephan Schwers, Dagmar Kubitza   +3 more
doaj   +1 more source

Pulsed Field Ablation for Atrial Fibrillation in Patients With Obesity: Procedural and Clinical Outcomes

Pacing and Clinical Electrophysiology, Volume 49, Issue 5, Page 636-643, May 2026.
ABSTRACT Background Procedural and clinical outcomes in patients with obesity undergoing catheter ablation for atrial fibrillation (AF) have been mixed. Clinical data in the context of pulsed field ablation (PFA) are currently limited in this patient cohort.
Francis J. Ha, Duron Prinsloo, Edwin Xu, Hui Chen Han, Nitesh Nerlekar, Adam J. Brown, Emily Kotschet   +6 more
wiley   +1 more source

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Frontiers in Pharmacology
BackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li   +9 more
doaj   +1 more source